Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Yao Hao Teo,Yao Neng Teo,Nicholas L. Syn,Cheryl Shumin Kow,Celine Shuen Yin Yoong,Benjamin Y. Q. Tan,Tiong‐Cheng Yeo,Chi‐Hang Lee,Weiqin Lin,Ching‐Hui Sia
DOI: https://doi.org/10.1161/jaha.120.019463
IF: 6.106
2021-02-26
Journal of the American Heart Association
Abstract:Background Recent studies have increasingly shown that sodium‐glucose cotransporter 2 (SGLT2) inhibitors may have beneficial cardiovascular and metabolic effects in patients without diabetes mellitus. Hence, we conducted a systematic review and meta‐analysis to determine the effect of SGLT2 inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. Methods and Results Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on August 30, 2020 for articles published from January 1, 2000 to August 30, 2020, for studies that examined the effect of SGLT2 inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. A random‐effects pairwise meta‐analysis model was used to summarize the studies. A total of 8 randomized‐controlled trials were included with a combined cohort of 5233 patients. In patients without diabetes mellitus, those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations, compared with those who were not treated (risk ratio, 0.78; P <0.001). We additionally found that treatment with SGLT2 inhibitors improved multiple metabolic indices. Patients on SGLT2 inhibitors had a reduction in body weight of −1.21 kg ( P <0.001), body mass index of −0.47 kg/m 2 ( P <0.001), systolic blood pressure of −1.90 mm Hg ( P =0.04), and fasting plasma glucose of −0.38 mmol/L ( P =0.05), compared with those without. There were no between‐group differences in NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels, waist circumference, diastolic blood pressure, glycated hemoglobin, low‐density lipoprotein cholesterol levels, and estimated glomerular filtration rates. Across our combined cohort of 5233 patients, hypoglycemia was reported in 22 patients. Conclusions SGLT2 inhibitors improve cardiovascular outcomes in patients without diabetes mellitus with heart failure. In patients without diabetes mellitus, SGLT2 inhibitors showed positive metabolic outcomes in weight and blood pressure control. Nonstandard Abbreviations and Acronyms SGLT2 sodium‐glucose cotransporter 2 Clinical Perspective What Is New? Among patients without diabetes mellitus, those with heart failure treated with sodium‐glucose cotransporter 2 inhibitors had a relative risk reduction in cardiovascular deaths and heart failure hospitalizations, compared with those who received placebo. Additionally, treatment with sodium‐glucose cotransporter 2 inhibitors in patients without diabetes mellitus improved their metabolic parameters including body weight and blood pressure. Across a combined cohort of 5233 patients without diabetes mellitus, hypoglycemia was reported in 22 patients. What Are the Clinical Implications? Future research of sodium‐glucose cotransporter 2 inhibitors in other subgroups of patients without diabetes mellitus, particularly those without heart failure, is warranted to determine its overall role in the management of patients without diabetes mellitus. Sodium‐glucose cotransporter 2 (SGLT2) inhibitor is a class of antihyperglycemic drugs increasingly used for patients with diabetes mellitus. 1 By blocking glucose reabsorption at the proximal renal tubule, SGLT2 inhibitors increase urinary glucose excretion and hence lower blood glucose in patients with diabetes mellitus. Beyond and independent of glycemic control, clinical trials have demonstrated an improvement in cardiovascular morbidity and mortality in patients with diabetes mellitus treated with SGLT2 inhibitors compared with placebo. 2 , 3 , 4 Furthermore, treatment with SGLT2 inhibitors in patients with diabetes mellitus was shown to be associated with metabolic benefits such as weight loss, 5 , 6 blood pressure reduction, 7 and improvement in renal function.<a class="tab-link" href="#ja -Abstract Truncated-
cardiac & cardiovascular systems